Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating ...
(PR-inside.com) New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer mod…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


